Stroke is a medical condition in which blood clot blocks the blood vessels and interrupts the blood flow to the brain, resulting in cell death. Under the guidelines of American Stroke Association, there are of 3 types of strokes: ischemic stroke (an obstruction within blood vessel that delivers blood to the brain), hemorrhagic stroke (weakened blood vessel rapture due to high blood pressure), and transient ischemic attack (identified by temporary clot). Stroke can be caused due to medical conditions such as high blood pressure, diabetes, heart disease or life style habits such as smoking, physically inactive lifestyle, alcohol abuse, obesity, and various others. Moreover, uncontrollable factors such as increasing age, male sex, heredity, and ethnicity contribute to stroke. According to the World Health Organization (WHO), in 2015, stroke is the second leading global cause of death after heart disease and it accounted for 11.8% of total deaths worldwide.
Request to download and view Sample Report: https://www.coherentmarketinsights.com/insight/request-sample/1483
Stroke management market is driven by advancements in technology and therapeutic along with increasing incidence of stroke and strict approval system is expected to hinder growth of global stroke management market.
Global Stroke Management Market Driver
The advancements in technology and facilities to diagnose stroke and discovery of novel drugs will drive growth of stroke management market. Technologies such as robotic-assisted angiography or exoskeleton soft suit for rehabilitation are the upcoming future of stroke management market. Moreover, an idea of Mobile Stroke Treatment Units (MSTU) was introduced in Germany in 2003 and was used in Berlin for the first time in 2008. The Prehospital Acute Neurological Treatment and Optimization of Medical care in Stroke Study (PHANTOM-S) in Germany reported that their MSTU significantly decreased stroke alert-to-treatment times from 76 minutes to 52 minutes, and significantly increased thrombolysis rates from 21% to 33% with no increase in the risk of intracerebral hemorrhage. Therefore, advancements in mobile stroke treatment units is expected to fuel growth of stroke management market.
Conventional stroke treatment aims at minimizing damage caused due to acute stroke by intravenous thrombolytics and endovascular thrombectomy, however, there is no proven cure for reversing the damage. It calls for a robust armamentarium of therapies for stroke treatment such as cell therapy, which has immense potential to propel the market in near future. Cell therapy can be used for re-vascularization after stroke and for reduction of cerebral inflammation. Phase II clinical trials of intravenous transplantation of autologous bone-marrow stem cells have reported safety and tolerability in stroke patients. Other pending clinical trials such as PISCES can also be considered as future candidates for clinical practice. Sonothrombolysis is another approach, which uses low-frequency ultrasound waves to cause thrombosis. The prototype for sonothrombolysis device is been tested by North Carolina State University and has filed a patent on the technology. Under equipped or untrained emergency medical service provider and strict governmental regulations on the approval of new drugs or advanced devices are some of the factors that are likely to hinder growth of stroke management market.
The narrow range of drugs available for the treatment of stroke offers wide options for research organizations and key players to excel the stroke management market by discovering novel drugs with less side-effects. Merger and acquisition is the key strategy to expand the stroke management market. In May 2017, Codman Neuro, a part of Johnson & Johnson acquired Neuravi Ltd., an Irish medical device company that manufactures advance revascularization device and EmboTrap is a device manufactured by this company. The EmboTrap platform was intended to address the critical need for rapid restoration of blood flow in stroke patients and combination of Neuravi’s expertise in clot research with Codman Neuro’s global resources aims to accelerate development in the field of acute ischemic stroke treatment. Furthermore, strong therapeutic pipeline of players will enhance growth of stroke management market. In 2018, NuvOx Pharma’s dodecafluoropentane emulsion (DDFPe) IV entered phase II clinical trials and DDFPe aims to deliver oxygen to hypoxic tissue of brain. Also, in 2018, DiaMedica Therapeutics Inc. announced DM199, a recombinant human tissue kallikrein, to enter phase II clinical trial and it is expected to be a breakthrough in stroke treatment.
Request to download and view full ToC: https://www.coherentmarketinsights.com/ongoing-insight/toc/1483
Global Stroke Management Market – Regional Analysis
On the basis of region, stroke management market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. The substantial upsurge of geriatric population in most of the economies is expected to drive growth of stroke management market. According to the United Nations Department of Economic and Social Affairs 2015 report, between 2015 and 2030 the number of people in the world at the age of 60 years or above is projected to increase by 56% from 901 million to 1.4 billion. Moreover, over the next 15 years the number of older persons is expected to grow fastest in Latin America and the Caribbean with a projection of around 71%, followed by Asia with 66%, Africa by 64%, Northern America by 41%, and Europe by 23% growth in old age population. Furthermore, Asia Pacific is the fastest growing stroke management market region due to upsurge in healthcare industry and increasing awareness for healthcare.
Global Stroke Management Market – Competitors
Other major companies contributing to the stroke management market include Abbott Laboratories, B. Braun Melsungen AG, Boston Scientific Corporation, GE Healthcare, GlaxoSmithKline Plc, Medtronic Plc, Merck & Co., Inc., and Cardinal Health.